Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
November 30, 2025MedicineOpen Access

Prognostic value of pan-immune-inflammation in breast cancer patients with lymph node metastasis and neoadjuvant therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZengyan WangWXWu XiongLYLeyi Yang

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows neoadjuvant therapy impacts progression-free survival in breast cancer with lymph node metastasis, highlighting prognostic significance of pan-immune-inflammation value.

Key Points

  • Patients with higher pan-immune-inflammation values experienced shorter progression-free survival with a P value of 0.002.
  • Progression-free survival was evaluated using Kaplan–Meier methodology and multivariate Cox regression analysis.
  • The analysis indicates pan-immune-inflammation value's predictive performance for survival at 1, 2, and 3 years with AUCs ranging from 0.802 to 0.867.
  • Results stress the importance of validating findings in larger, multicenter prospective studies for clinical applications.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/692b94581d383f2b2a378e44https://doi.org/10.1097/md.0000000000045713
View Full Paper
Ask AI
Bookmark
Share